InnoCan Pharma Corporation (INNO.CN)

CAD 0.19

(-7.5%)

Market Cap (In CAD)

53.08 Million

Revenue (In CAD)

13.65 Million

Net Income (In CAD)

-4.7 Million

Avg. Volume

71.63 Thousand

Currency
CAD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.18-0.34
PE
-
EPS
-
Beta Value
2.96
ISIN
CA45783P1027
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Ms. Iris Bincovich
Employee Count
-
Website
https://innocanpharma.com
Ipo Date
2019-09-25
Details
InnoCan Pharma Corporation, a pharmaceutical company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Poland, France, and internationally. The company engages in the research and development of COVID-19 and other condition treatment by using CBD loaded exosomes; and CBD loaded liposomes. Its product includes CBD eye serum, CBD face oil, CBD face cream, CBD facial serum, CBD sleeping mask, CBD recovery lotion, and the Relief & Go spray. The company is also involved in the commercialization and sale of branded CBD integrated pharmaceutical and topical treatment products. InnoCan Pharma Corporation was incorporated in 2018 and is headquartered in Calgary, Canada.